💥 Gate Square Event: #PostToWinFLK 💥
Post original content on Gate Square related to FLK, the HODLer Airdrop, or Launchpool, and get a chance to share 200 FLK rewards!
📅 Event Period: Oct 15, 2025, 10:00 – Oct 24, 2025, 16:00 UTC
📌 Related Campaigns:
HODLer Airdrop 👉 https://www.gate.com/announcements/article/47573
Launchpool 👉 https://www.gate.com/announcements/article/47592
FLK Campaign Collection 👉 https://www.gate.com/announcements/article/47586
📌 How to Participate:
1️⃣ Post original content related to FLK or one of the above campaigns (HODLer Airdrop / Launchpool).
2️⃣ Content mu
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.